华润三九(000999) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached CNY 31.63 billion, an increase of 14.53% compared to the previous year[4] - Net profit attributable to shareholders was CNY 3.42 billion, reflecting a year-on-year growth of 1.60%[7] - Basic earnings per share for 2025 were CNY 2.06, up 1.98% from CNY 2.02 in the previous year[4] - The weighted average return on equity decreased to 16.08%, down 1.25% from the previous year[4] - The net asset per share attributable to shareholders decreased to CNY 13.32, down 14.06% from CNY 15.50[4] Assets and Equity - Total assets as of the end of 2025 amounted to CNY 58.81 billion, a significant increase of 46.72% year-on-year, primarily due to the acquisition of Tian Shi Li Pharmaceutical Group[6] - The equity attributable to shareholders increased to CNY 22.17 billion, a growth of 11.40% compared to the beginning of the year[4] - The company implemented a capital reserve distribution plan, resulting in an increase in the share capital by 29.58%[5] Strategic Initiatives - The company expanded its R&D pipeline and optimized its business layout to strengthen its competitive advantage in the industry[7] - The company aims to solidify its position as a leading player in the industry by focusing on innovation and brand development[7]